Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Gamida Cell $75 million follow-on offering
Davis Polk advised the representatives of the underwriters in connection with the $75 million SEC-registered follow-on…
ImmunityBio merger with NantKwest
Davis Polk is advising Goldman Sachs & Co. LLC and Lazard Frères & Co. LLC as financial advisers to ImmunityBio, Inc…
Solid Biosciences $90 million common stock PIPE offering
Davis Polk advised the placement agent in connection with a private placement pursuant to Rule 4(a)(2) by Solid…
Atara Biotherapeutics $175 million common stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a…
Seer $336 million IPO and concurrent private placement
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 10,592…
Oak Street Health $297.9 million secondary offering
Davis Polk advised the joint book-running managers in connection with the $297.9 million secondary offering of 6,477…
BeiGene $340 million secondary offering
Davis Polk advised the underwriter in connection with the $340 million SEC-registered offering of 1,511,546 American…
Notre Dame Intermédica R$3.8 billion equity offering
Davis Polk advised Notre Dame Intermédica Participações S.A. in connection with the equity offering by Bain Capital, the…
RAPT Therapeutics $100 million at-the-market offering
Davis Polk advised the sales agents on the SEC-registered at-the-market offering by RAPT Therapeutics, Inc. of its…
Revance Therapeutics $125 million at-the-market offering
Davis Polk advised the sales agent on the SEC-registered at-the-market offering by Revance Therapeutics, Inc. of its…